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Mutations in presenilin 1 (PSEN1), presenilin 2 (PSEN2), and amyloid precursor protein (APP) are major
genetic causes of early-onset Alzheimer’s disease (EOAD). Clinical heterogeneity is frequently observed in
patients with PSEN1 and PSEN2 mutations. Using whole exome sequencing, we screened a Dutch cohort
of 68 patients with EOAD for rare variants in Mendelian Alzheimer’s disease, frontotemporal dementia,
and prion disease genes. We identiﬁed 3 PSEN1 and 2 PSEN2 variants. Three variants, 1 in PSEN1
(p.H21Profs*2) and both PSEN2 (p.A415S and p.M174I), were novel and absent in control exomes. These
novel variants can be classiﬁed as probable pathogenic, except for PSEN1 (p.H21Profs*2) in which the
pathogenicity is uncertain. The initial clinical symptoms between mutation carriers varied from
behavioral problems to memory impairment. Our ﬁndings extend the mutation spectrum of EOAD and
underline the clinical heterogeneity among PSEN1 and PSEN2 mutation carriers. Screening for Alz-
heimer’s diseaseecausing genes is indicated in presenile dementia with an overlapping clinical diagnosis.
 2019 Elsevier Inc. All rights reserved.1. Introduction
Early-onset Alzheimer’s disease (EOAD) accounts for 1%e2% of
all Alzheimer’s disease (AD) cases. It can be caused by mutations in
presenilin 1 (PSEN1), presenilin 2 (PSEN2), and amyloid precursor
protein (APP) in an autosomal dominant inheritance pattern (Goate
et al., 1991; Levy-Lahad et al., 1996; Sherrington et al., 1995). To
date, more than 280 mutations have been found in PSEN1, PSEN2,
and APP (www.molgen.ua.ac.be/ADMutations) (Cruts et al., 2012).
Presenilin 1 and presenilin 2 proteins are both key components
of gamma secretases, which process APP by cleaving into amyloid
beta (Ab) fragments (Karch et al., 2014). Mutation in these genes
impairs the proteolytic activity of gamma secretases, resulting in a
disbalance of Ab40 and Ab42 (Weggen and Beher, 2012). Consider-
able heterogeneity is found in the clinical presentation of PSEN1
and PSEN2 mutation carriers, including initial behavioral, language,
and dysexecutive problems, myoclonus, seizures, spasticity, and
hallucinations (Jayadev et al., 2010; Ryan et al., 2016). The age at
onset among mutation carriers also varies greatly, ranging from 23
to 71 years, even in families with the same mutation (Ryman et al.,gy, Erasmus Medical Centre
, 3015 CE Rotterdam, the
van Swieten).
ll rights reserved.2014). Neuropathologically, PSEN1 mutation carriers often have
more neuronal loss in the frontotemporal cortex than sporadic AD
cases (Shepherd et al., 2009). Furthermore, more neocortical senile
plaques and higher Ab42/Ab40 plaque ratios are observed in PSEN1
and PSEN2 mutation carriers than sporadic AD cases.
In this study, we assessed the contribution of rare variants in
Mendelian AD (PSEN1, PSEN2, and APP), frontotemporal dementia
(FTD; MAPT, GRN, TARDBP, VCP, CHMP2B, FUS, and TBK1), and prion
diseasegenes (PRNP) inaDutchcohortof 68patientswithEOADusing
whole exome sequencing (WES). We found 3 novel and 2 reported
variants in PSEN1 and PSEN2. We describe the clinical and available
pathological features of the PSEN1 and PSEN2 variant carriers.
2. Methods
2.1. Subjects
Patients were included either by referral to the Department of
Neurology of the Erasmus Medical Center (Rotterdam, the
Netherlands) or by visits to (nursing) homes. Patients underwent a
clinical examination, neuropsychological assessment, neuro-
imaging, and if indicated, a lumbar puncture. The diagnosis of
probable AD was established according to the National Institute of
Neurological and Communicative Disorders and Stroke-Alzheimer’s
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criteria for AD (McKhann et al., 2011). EOAD was deﬁned as an age
at onset of 65 years. Family history was deﬁned as positive if the
patient had at least one ﬁrst degree relative with dementia. Cere-
brospinal ﬂuid (CSF) proﬁle consistent with AD was deﬁned as Ab42
< 550 pg/mL, tau> 375 pg/mL, and phospho-tau> 53 pg/mL or tau/
Ab42 > 0.52 (Duits et al., 2015). We selected 68 patients with EOAD
for WES based on their initial clinical diagnosis of probable AD and/
or CSF proﬁle consistent with AD, as mentioned previously. CSF was
present in 41 patients, and pathological diagnosis of AD was found
in 4 patients.
The study was approved by the Medical Ethical Committee of
the Erasmus Medical Center, and written informed consent was
obtained from all participants or their legal representatives.2.2. Genetic analysis
DNA from all samples was prepared with the Illumina TruSeq
Paired-End Library Preparation Kit, and 100-base-pair paired-end
reads were acquired by sequencing the libraries on a HiSeq 2000.
Exomes were captured using NimbleGen SeqCap EZ Exome Capture
Kit v2. All data were generated at the Human Genomics Facility
(HuGeF; www.glimdna.org) at the Erasmus Medical Center Rot-
terdam. Sequencing reads were aligned to the hg19 human genome
assembly using BWA-MEM (version 0.7.3a) (Li and Durbin, 2009),
followed by duplicate marking and sorting alignments by Picard
Tools (version 1.9) (Li and Durbin, 2009). Subsequently, Genome
Analysis Tool Kit (version 3.3) was used to perform indel realign-
ment, base quality score recalibration, and variant calling (McKenna
et al., 2010). Subsequently, we used variant quality score recali-
bration from Genome Analysis Tool Kit to ﬁlter out low-quality
variants using thresholds of 90 for single-nucleotide variants and
50 for indels. All individuals in the WES data were checked for sex
concordance using Plink (Purcell et al., 2007). Variants were an-
notated using ANNOVAR (Wang et al., 2010).
We focused on missense, nonsense, splicing, and frameshift
variants in Mendelian AD (PSEN1, PSEN2 and APP), FTD (MAPT, GRN,
TARDBP, VCP, CHMP2B, FUS, and TBK1), and prion disease genes
(PRNP) as described in previous studies (Blauwendraat et al., 2016;
Perrone et al., 2018). Any identiﬁed variants with a minor allele
frequency of 0.1% in the genome aggregation database (gnomAD),
Healthy EXomes (HEX), Genome of the Netherlands, and in-house
WES data from the Rotterdam Study were ﬁltered out (Guerreiro
et al., 2018a,b; Lek et al., 2016; The Genome of the Netherlands,
2014; van Rooij et al., 2017). Subsequently, we interpreted the
identiﬁed variants using the Alzheimer Disease & Frontotemporal
Dementia Mutation Database (www.molgen.ua.ac.be/admutations/
) (Cruts et al., 2012), AlzForum (www.alzforum.org/mutations)
database, and a literature search. Combined Annotation Dependent
Depletion (CADD) score was used to predict the pathogenicity ofTable 1
Rare variants in PSEN1 and PSEN2 identiﬁed in the EOAD cohort
Variant interpretation Gene Exon Nucleotide change Protein
Known pathogenic
PSEN1 4 c.236C>T p.A79V
PSEN1 8 c.791C>T p.P264L
Probable pathogenica
PSEN2 7 c.522G>A p.M174I
PSEN2 13 c.1243G>T p.A415S
Variant of unknown signiﬁcance
PSEN1 3 c.62delA p.H21Pr
Key: CADD, Combined Annotation Dependent Depletion; EOAD, early-onset Alzheimer
available; PSEN1, presenilin 1 (NM_000021); PSEN2, presenilin 2 (NM_000447); TM, tran
a Pathogenicity classiﬁcation based on the algorithm proposed by Guerreiro et al. (201the variants (Kircher et al., 2014). Variants in PSEN1 and PSEN2were
further classiﬁed according to the algorithm described by Guerreiro
et al. (Guerreiro et al., 2010). All identiﬁed variants were conﬁrmed
by Sanger sequencing. Screening of chromosome 9 open reading
frame (C9orf72) repeat expansions was performed on selected cases
with upper and/or lower motor neuron signs or a family history
positive for motor neuron sign.
2.3. Histology and immunohistochemistry
The Netherlands Brain Bank performed brain autopsy according
to their Legal and Ethical Code of Conduct. Tissue blocks taken from
all cortical areas, hippocampus, amygdala, basal ganglia, substantia
nigra, pons, medulla oblongata, cerebellum, and cervical spinal cord
were embedded in parafﬁn blocks and subjected to routine staining
with hematoxylin and eosin, periodic acid-Schiff reaction, and sil-
ver staining. The slides were also immunochemically stained with
Anti-b-Amyloid, 1e42 (12F4, dilution 1:400; BioLegend), Anti-b-
Amyloid, 1e40 (11A50-B10, dilution 1:400; BioLegend), a-synuclein
(NCL-ASYN, dilution 1:10,000; Novocastra), and AT8 (MN1020,
dilution 1:200; Thermo Fisher Scientiﬁc). Braak stage was ascer-
tained according to the revised National Institute on Aging-
eAlzheimer’s Association guidelines (Montine et al., 2012).
3. Results
The mean age at onset in our cohort of 68 EOAD cases was
57.7 years (range 51e65). A positive family history was found in 39
cases (57%).
3.1. Mutation screening
After ﬁltering, we found 5 rare variants, 3 in PSEN1 and 2 in
PSEN2 (Table 1). Two variants (p.A79V and p.P264L) in PSEN1 were
previously described in EOAD cases (Campion et al., 1995; Cruts
et al., 1998). One single PSEN1 (p.H21Profs*2) (Fig. 1) and both
PSEN2 (p.A415S and p.M174I) variants were novel. No rare variants
were found in APP gene. All variants, except one in PSEN1 (p.A79V),
were unknown in gnomAD, HEX, GoNL, and exome data from the
Rotterdam Study. No rare variants in SORL1, TREM2, or ABCA7 have
been found in the 5 PSEN carriers. The main clinical features of the
PSEN1 and PSEN2 mutations carriers are summarized in Table 2.
3.2. Novel PSEN1 mutation p.H21Profs*2
PSEN1 p.H21Profs*2 is located in exon 3, which codes for the N-
terminal domain. The female carrier, aged 60 years, presented with
progressive memory impairment, followed by problems in orien-
tation, housekeeping, verbal expression, and loss of initiative.
Neurological examination 1 year after onset showed aMinieMentalchange Status Protein domain GnomAD CADD phred score
rs63749824 N-terminal 1.44  1002 33
rs63750301 HL-VI a 4.08  1003 35
Novel HL-I 0 20.8
Novel TM-IX 0 33
ofs*2 Novel N-terminal 0 NA
’s disease; GnomAD, genome aggregation database; HL, hydrophilic loop; NA, not
smembrane.
0).
Fig. 1. Electropherogram of PSEN1 p.H21Profs*2 variant.
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left-sided cogwheel sign during risperidone medication prescribed
for nightmares. Neuropsychological assessment showed deﬁcits in
multiple domains including memory, executive functions, and vi-
sual perception; however, several tests were prematurely ended
due to poor performance. MRI showed global brain atrophy and
extensive white matter lesions in the parieto-occipital region.
During follow-up, the patient was treatedwith acetylcholinesterase
inhibitors until death, aged 65 years. Family history revealed a
mother with dementia with an age at onset of 60 years.3.3. Novel PSEN2 mutation p.M174I
The p.M174I variant in the PSEN2 genewas identiﬁed in a female
patient who developed memory problems at the age of 53 years.
This variant is located in the hydrophilic loop domain of the pre-
senilin 2 protein. The patient developed progressive anomia andTable 2
Clinical characteristics of the mutation carriers in PSEN1 and PSEN2
Gene Protein
change
Diagnosis AAO Family
history
Initial presentation Be
sy
PSEN1 p.H21Profs*2 AD 60 Positive Memory
impairment
No
PSEN1 p.A79V AD/DLB 64 Positive Behavioral changes Su
PSEN1 p.P264L AD/FTD þ PLS 56 Positive Gait disturbance La
PSEN2 p.M174I AD/FTD 51 Positive Memory
impairment
De
PSEN2 p.A415S AD 59 Negative Gait disturbance No
Symptom presentation referred to the clinical presentation at disease onset.
Key: AAO, age at onset; AD, Alzheimer’s disease; DLB, Dementia with Lewy bodies; FTD,
presenilin 2.
a Behavioral symptoms at ﬁrst visit.
b Nightmares treated with risperidone.memory impairment within the ﬁrst 3 years. She had a depressed
mood and was apathetic. Neurological examination (2 years after
onset) showed an MMSE score of 18/30, short-term memory
impairment, dyscalculia, bradyphrenia, and apraxia. Over time, the
patient developed behavioral changes, including aggression, rest-
lessness, obsessive thinking, blunted emotions, and binge eating.
MRI showed generalized cerebral atrophy most prominent of the
frontal lobes; CSF was not available. The clinical diagnosis was
either presenile AD with frontal presentation or a behavioral
variant of FTD. After admission to a nursing home, she developed
hallucinations, seizures, spasticity, and mutism. She died o pneu-
monia at the age of 64 years. The patient’s mother had been diag-
nosed with AD at the age of 75 years.
Neuropathological examination of the p.M174I PSEN2 carrier
revealed severe neuronal loss and gliosis of the frontal, temporal,
and parietal cortices, cornu ammonis (CA) region 1 of the hippo-
campus and to a lesser extent in the other CA regions, subiculum,
and occipital cortex. Abundant AT8-positive threads and tangles
accompanied by many Ab-positive senile plaques of variable size
andmorphologywere found in the neocortex, predominantly in the
frontal cortex, and to a lesser extent in the parietal and temporal
cortices and CA1 of the hippocampus (Fig. 2AeE). Classical, pre-
dominantly Ab42-positive plaques with a dense core were seen in
5%e10% of the plaques. Only a small number of plaques were
stained Ab40-positive (Fig. 2B and C). The severe involvement of the
frontal, temporal, and parietal cortices is consistent with advanced
stage AD, Braak stage 6, A3B3C3 (Montine et al., 2012). Further-
more, many a-synucleinepositive Lewy bodies (LBs) were seen
(Fig. 2F), especially in the amygdala and parahippocampal cortex
and a few in the substantia nigra and brainstem.3.4. Novel PSEN2 mutation p.A415S
The PSEN2 (p.A415S) variant, located in the transmembrane IX
domain, was identiﬁed in a female patient aged 59 years who
presented with memory impairment and gait disturbance. She
developed difﬁculties in verbal expression with problems in word
ﬁnding, hallucinations, andmyoclonus. Her grandmother, aunt, and
uncle also had dementia, all with onset age> 65 years. Neurological
examination revealed an MMSE score of 17/30, hyperreﬂexia in the
arms and legs, and a spastic gait. Neuropsychological assessment
showed impairment in memory, language, perceptuospatial skills,
and praxis. MRI showed global cerebral and cerebellar atrophy. Her
CSF was compatible with an AD proﬁle with decreased Ab (203 pg/
mL), increased phospho-tau (95 pg/mL), and total tau (551 pg/mL).
Cognitive functions including verbal expression and motor func-
tioning deteriorated over the following 3 years, and she was
admitted to a nursing home. At a later stage, aged 65 years, she
became mutistic and wheelchair bound.havioral
mptomsa
Myoclonus Seizure Delusions/
hallucinations
Spasticity Extrapyramidal
sign
No No Nob No No
spicious No No Yes No Yes
bile affect No No No Yes No
pressed Yes Yes Yes Yes Yes
Yes No Yes Yes Yes
frontotemporal dementia; PLS, primary lateral sclerosis; PSEN1, presenilin 1; PSEN2,
Fig. 2. Pathological features of the PSEN2 p.M174I mutation carrier. Histological section and immunostaining in the frontal cortex and hippocampus of the PSEN2 p.M174I carrier.
Hematoxylin and eosin staining of the frontal cortex showed many plaques and eosinophilic bodies (A). Extensive numbers of Ab42-immunoreactive (IR) plaques were observed in
all layers of the frontal cortex (B), whereas only small numbers of Ab40-IR plaques were found (C). Immunostaining with tau protein showed many AT8-IR tangles and small threads
in the frontal (D) and hippocampus (E). Numerous Lewy bodies positive for a-synuclein were seen in the amygdala (F).
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The patient with PSEN1 p.A79V mutation presented with
cognitive impairment, delusions, hallucinations, and parkinsonism
suggestive for probable dementia with Lewy bodies (DLBs) when
aged 64 years (McKeith et al., 2005). Family history revealed 5
siblings and a father who had AD before the age of 65 years. Three of
the affected siblings also suffered from hallucinations. DNA was
only available in 1 sister with AD and onset age of 74 years who also
carried the PSEN1 p.A79V mutation.
The second mutation, PSEN1 p.P264L, was found in a patient
aged 56 years who presented with gait disturbance. Memory
impairment, behavioral changes, and impairment in word
comprehension and word ﬁnding were also observed early in the
disease process. The clinical diagnosis was suspected behavioral
variant of FTD or a frontal variant of AD with primary lateral scle-
rosis. The patient’s grandmother, mother, and 1 sister also had
dementia. Screening on C9orf72 was negative.
4. Discussion
We identiﬁed 1 novel frameshift deletion in PSEN1 (p.H21Profs*2)
and 2 novel missense in PSEN2 (p.A415S and p.M174I) using theWES
in a Dutch cohort with EOAD. These novel variants were not present
in the public sequencing database and population-match exomes. In
addition, we found 2 known PSEN1 variants (p.A79V and p.P264L),
reported as pathogenic in previous studies (Cruchaga et al., 2012).
The PSEN1 and PSEN2 variant carriers had variable clinical presen-
tation including memory impairment, behavioral changes, and py-
ramidal and extrapyramidal symptoms.
The ﬁrst novel variant, PSEN1 p.H21Profs*2, is a frameshift mu-
tation resulting in a premature stop codon in the sequences of exon
3, and as a consequence, a truncated protein. Frameshift deletions
in PSEN1 and PSEN2 were reported as a possible genetic cause of
EOAD; however, the pathogenicity is debatable (El Kadmiri et al.,
2014; Jayadev et al., 2010; Perrone et al., 2018). Variable pheno-
types of the frameshift deletion mutation carriers including AD,
mild cognitive impairment, FTD, and amyotrophic lateral sclerosis
have been reported. Segregation or functional studies supportingthe pathogenicity of these mutations are scarce. One study reported
a reduced presenilin 2 protein expression in the lymphoblast cells
of a PSEN2 (p.G359Lfs*74) mutation carrier compared with control,
but a reduced presenilin 2 protein expression was also found in a
mutation carrier with autopsy conﬁrmed frontotemporal
lobar degeneration (Perrone et al., 2018). We classiﬁed the patho-
genicity of our novel variant as a variant of uncertain signiﬁcance, as
we were unable to investigate the functional effect due to the lack
of additional blood or brain tissue from the patient.
The second novel variant, PSEN2 p.M174I, was classiﬁed as
probable pathogenic according to the algorithm proposed by
Guerreiro et al. (Guerreiro et al., 2010) based on reported mutation
in the same codon (p.M174V) and the altered Ab level at neuropa-
thology. However, conﬂicting results about the pathogenicity of
p.M174V have been reported (Cruchaga et al., 2012; Fernandez
et al., 2017; Guerreiro et al., 2010; Lohmann et al., 2012).
Although the pathogenicity of PSEN2 p.M174V is unclear, our case
carried a different PSEN2 variant with a high CADD score of 20.8,
which is unknown in gnomAD. Furthermore, the presence of a
higher number of neocortical senile plaques with a higher Ab42/
Ab40 ratio in our case is consistent with the reported pathological
features of PSEN1 and PSEN2 mutation carriers (Shepherd et al.,
2009); therefore, this variant may be causative for AD.
The third novel variant, PSEN2 p.A415S, was classiﬁed as prob-
able pathogenic based on (1) conserved residues in PSEN1 A431; (2)
previously reported mutations in the same codon (A431E and
A431V) (Matsushita et al., 2002; Rogaeva et al., 2001); and (3) CSF
proﬁle with low Ab and high phospho-tau and total tau indicative
for AD. Furthermore, the damaging effect of this variant was also
supported by a high CADD score of 33.
The atypical AD symptoms of the mutation carriers in our study
have been frequently reported in PSEN1 carriers (Ryan et al., 2016).
Up to 16% of PSEN1 carriers had an atypical presentation, and about
8% of PSEN1 mutations carriers presented with behavioral changes
at onset. Similar to previous reports, the PSEN1 p.P264L carrier in
our study also had symptoms consistent with spastic paraparesis
(Jacquemont et al., 2002). Spastic paraparesis is present in 25% of
PSEN1 cases and is frequently associated with mutations beyond
codon 200 (Ryan et al., 2016; Shea et al., 2016).
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hallucinations during the disease course. In one (PSEN1 p.A79V)
carrier, the clinical diagnosis was suspect for DLBs (McKeith et al.,
2005) or AD because of the presence of hallucinations and
parkinsonism together with memory impairments. Interestingly, 3
siblings of this carrier also had hallucinations, but prominent
cognitive impairment made the clinical diagnosis of ADmore likely.
The association of PSEN1 p.A79V with DLBs as phenotype has been
reported previously (Meeus et al., 2012). Notably, the DLB pheno-
type has also been reported in a patient with PSEN2 p.A85V mu-
tation, which is homolog to PSEN1 p.A79V (Piscopo et al., 2008).
Neuropathological examination of the PSEN2 p.A85V carrier
showed abundant neocortical LBs and AD pathology, suggesting a
link between this mutation and LB pathology. Up to 96% of LB pa-
thology has been reported in familial AD with PSEN1 mutations,
whereas lower percentages have been reported in AD with PSEN2
mutation (64%) and sporadic AD (60.7%) (Hamilton, 2000; Leverenz
et al., 2006). However, this difference in LB pathology between
these groups has not been conﬁrmed in other studies (Lippa et al.,
1998; Ringman et al., 2016). Unfortunately, no brain tissue of the
PSEN1 p.A79V carrier was present to examine the presence of LB
pathology. Another possibility for the DLB phenotype in our case
may be the presence of another gene mutation for DLBs. Recent
studies identiﬁed the genetic association of variants in the gluco-
cerebrosidase (GBA) gene with DLBs (Geiger et al., 2016; Guerreiro
et al., 2018a,b; Nalls et al., 2013). In our cases, screening of GBA
did not identify any rare variants in this gene (data not shown).
Nevertheless, the presence of unidentiﬁed genetic factor(s)
contributing to the DLB phenotype cannot be ruled out.
We used exome sequencing to screen for mutations in known
dementia genes. Although we were able to identify small deletion
and missense mutations using this method, large deletion such as
DeltaE9 in PSEN1 (Crook et al., 1998), C9orf72 repeat expansions,
and copy number variations variants can be missed, and thus, we
may underestimate the frequency of the mutations. However, these
mutations in PSEN1 and PSEN2 are rare, and the observed frequency
of PSEN variants in 7% of our cohort of 68 EOAD cases is in line with
those reported earlier by Brouwers et al. (Brouwers et al., 2008).
Another limitation is that the follow-up time in most patients was
limited to a few years, and we cannot rule out that additional
symptoms may have developed later during their disease course.
Finally, DNA was only available from a sister with AD of the p.A79V
mutation carrier; we were unable to include other family members
of the other mutation carriers. Therefore, segregation analysis could
not be performed for these mutation carriers.
Our study provides further insights into the genetics of AD by
identifying 3 novel mutations in PSEN1 and PSEN2 and highlights
the clinical heterogeneity of the presenilin mutation carriers.
Although overlapping clinical diagnosis with FTD or DLBs was
found in some patients, we were unable to identify other probable
pathogenic dementia-causing genes besides PSEN1 and PSEN2.
Genetic screening of AD causative genes is valuable in patients with
clinically suspected EOAD with atypical clinical features, particu-
larly in familial cases.
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